 |
|
5- Reductase Inhibitors and Risk of Hip Fracture—Reply
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
In Reply: In response to Dr Bollu and colleagues, the duration of use of finasteride was highly correlated with total dose. The median (25th-75th percentile) time from first prescription to fracture/index date was 1.6 years (0.8-3.7 years) for case patients and 2.1 years (0.9-3.8 years) for control patients. When stratified by time since first prescription for finasteride (overall median), the inverse relationship with hip fracture was fairly consistent across categories of cumulative dose among men with more remote first prescriptions (odds ratio [OR], 0.61; 95% confidence interval [CI], 0.31-1.19; OR, 0.69; 95% CI, 0.37-1.26; and OR, 0.54; 95% CI, 0.25-1.15 for men with cumulative doses of 10-500 mg, 501-2750 mg, and  2751 mg, respectively). For men with more recent first prescriptions, the relationship was attenuated with larger cumulative doses (OR, 0.68; 95% CI, 0.38-1.22; OR, 1.17; 95% CI, 0.69-1.99; and OR, 1.66; 95% CI, 0.32-10.69 for men with cumulative doses . . . [Full Text of this Article]
Steven J. Jacobsen, MD, PhD
steven.j.jacobsen@kp.org
Jiaxiao M. Shi, PhD
Department of Research and Evaluation
Kaiser Permanente Southern California
Pasadena
Ronald K. Loo, MD
Department of Urology
Bellflower Medical Center
Bellflower, California
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
Association Between 5- Reductase Inhibition and Risk of Hip Fracture
Steven J. Jacobsen, T. Craig Cheetham, Reina Haque, Jiaxiao M. Shi, and Ronald K. Loo
JAMA. 2008;300(14):1660-1664.
ABSTRACT
| FULL TEXT
RELATED LETTER
5- Reductase Inhibitors and Risk of Hip Fracture
Madhavi Bollu, Andres C. Marte-Grau, and Ravi K. Bobba
JAMA. 2009;301(9):935.
EXTRACT
| FULL TEXT
|
